Ionis Pharmaceuticals, Inc.
A biotech pioneer that designs medicines that target RNA—the body's genetic messengers—to treat diseases that were long considered "undruggable." Its medicines include SPINRAZA for spinal muscular atrophy and newer launches like WAINUA, TRYNGOLZA, and DAWNZERA, used mainly by patients with rare, neurological, and cardiometabolic conditions. Founded in 1989, it was originally named Isis Pharmaceuticals after the Egyptian goddess of healing, but renamed itself Ionis in 2015 to shake an unfortunate association with the militant group of the same name.
Granted 2.40M · Sold 2.77M
Granted 1.39M · Sold 1.18M
Granted 248.7K · Sold 122.0K
Granted 158.5K · Sold 113.2K
Granted 661.8K · Sold 514.7K
Granted 855.1K · Sold 745.4K
Granted 184.7K · Sold 131.3K
Granted 101.3K · Sold 59.7K
Granted 200.3K · Sold 164.6K
Granted 72.0K · Sold 65.0K
Granted 691.6K · Sold 625.8K
Granted 167.6K · Sold 108.0K
Granted 584.3K · Sold 504.4K
Granted 90.1K · Sold 44.0K
Granted 34.3K · Bought 20.0K
Granted 160.2K · Sold 123.8K
Granted 242.7K · Sold 249.7K
Granted 1.39M · Sold 1.33M
Granted 52.5K · Sold 15.5K
Granted 316.4K · Bought 16.0K · Sold 321.4K
Granted 192.9K · Sold 202.9K
Granted 62.4K · Sold 58.6K
Granted 68.7K · Sold 47.0K
Granted 29.2K · Sold 10.0K
Granted 122.7K · Sold 114.3K
Granted 14.2K
Granted 20.0K · Sold 24.6K
Granted 60.0K · Sold 60.0K
Granted 11.0K · Sold 4.4K
Granted 7.9K
Granted 30.0K · Sold 30.0K
Granted 31.7K · Sold 31.7K
Granted 3.5K
Granted 99.2K · Sold 99.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Crooke Stanley TExec Chairman of the Board, Director · 583 transactions | — | 533.0Kas of Jan 2021 | 2.40M | — | 2.77M |
| Monia Brett PChief Executive Officer, Director · 204 transactions | — | 245.6K | 1.39M | — | 1.18M |
| Berthelsen Spencer RDirector · 88 transactions | — | 156.1K | 248.7K | — | 122.0K |
| Baroldi JosephEVP, Chief Business Officer · 49 transactions | — | 98.9K | 158.5K | — | 113.2K |
| Hougen Elizabeth LEVP, Finance & CFO · 153 transactions | — | 82.7K | 661.8K | — | 514.7K |
| Bennett C FrankEVP, Chief Scientific Officer · 264 transactions | — | 80.6K | 855.1K | — | 745.4K |
| Schneider EugeneEVP, Chf Clinical Develop Ofcr · 34 transactions | — | 77.1K | 184.7K | — | 131.3K |
| Birchler BrianEVP, Corp and Development Ops · 28 transactions | — | 67.5K | 101.3K | — | 59.7K |
| Swayze EricEVP Research · 63 transactions | — | 64.3K | 200.3K | — | 164.6K |
| Kordasiewicz Holly B.EVP, Chief Development Officer · 8 transactions | — | 63.4K | 72.0K | — | 65.0K |
| O'Neil Patrick R.EVP CLO & General Counsel · 347 transactions | — | 61.5K | 691.6K | — | 625.8K |
| Muto Frederick TDirector · 51 transactions | — | 61.1Kas of Jul 2022 | 167.6K | — | 108.0K |
| Geary Richard SEVP, Chief Development Officer · 224 transactions | — | 59.7K | 584.3K | — | 504.4K |
| Herman Joan EDirector · 17 transactions | — | 58.1K | 90.1K | — | 44.0K |
| Hayden Michael RDirector · 15 transactions | — | 56.3Kas of Jul 2025 | 34.3K | 20.0K | — |
| Loscalzo JosephDirector · 45 transactions | — | 54.1K | 160.2K | — | 123.8K |
| Wender Joseph HDirector · 80 transactions | — | 52.0K | 242.7K | — | 249.7K |
| Parshall B LynneDirector · 346 transactions | — | 51.9K | 1.39M | — | 1.33M |
| Cadoret-Manier OnaizaEVP,Chf GL Pdt Str & Oper Ofc · 17 transactions | — | 35.8Kas of Feb 2024 | 52.5K | — | 15.5K |
| Klein Joseph IIIDirector · 198 transactions | — | 31.6K | 316.4K | 16.0K | 321.4K |
| Ecker David JVice President · 58 transactions | — | 28.7Kas of Sep 2008 | 192.9K | — | 202.9K |
| Diaz Allene M.Director · 14 transactions | — | 28.7K | 62.4K | — | 58.6K |
| Jenne KyleEVP, Chf GL Pdt Str Ofcr · 10 transactions | — | 23.7K | 68.7K | — | 47.0K |
| Castleman BreauxDirector · 22 transactions | — | 19.2Kas of Jul 2020 | 29.2K | — | 10.0K |
| Devers Shannon L.EVP, Chief Human Resources Ofc · 33 transactions | — | 16.3K | 122.7K | — | 114.3K |
| Reikes Peter NDirector · 6 transactions | — | 14.2Kas of Oct 2021 | 14.2K | — | — |
| Wedel Mark KVP & Chief Medical Officer · 15 transactions | — | 11.8Kas of Jul 2007 | 20.0K | — | 24.6K |
| Treble Michael JVice President, Pres of Ibis · 11 transactions | — | 10.0Kas of Aug 2008 | 60.0K | — | 60.0K |
| Boyce SarahChief Business Officer · 13 transactions | — | 8.9Kas of Jan 2018 | 11.0K | — | 4.4K |
| Yang Michael J.Director · 3 transactions | — | 7.9K | 7.9K | — | — |
| Reed John CDirector · 8 transactions | — | 4.9Kas of Sep 2012 | 30.0K | — | 30.0K |
| Brown Richard KVice President · 41 transactions | — | 4.6Kas of Mar 2006 | 31.7K | — | 31.7K |
| McDevitt DamienChief Business Officer · 3 transactions | — | 3.8Kas of Jul 2019 | 3.5K | — | — |
| Levin Arthur AVice President · 39 transactions | — | 1.7Kas of Apr 2007 | 99.2K | — | 99.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -9.82M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.